Conference Coverage
Reducing the Risk of PML During MS Treatment
NASHVILLE—For patients with multiple sclerosis (MS) who receive treatment with natalizumab, progressive multifocal...
—Randy Dotinga
Suggested Reading
Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017;12:59-63.
Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009;72(5):402-409.
Landi D, De Rossi N, Zagaglia S, et al. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology. 2017;88(12):1144-1152.